Meta AI (FAIR)

Orakl Oncology uses Meta's DINOv2 to accelerate cancer organoid analysis and drug response prediction

Orakl Oncology, a spinoff from the Gustave Roussy Institute, has deployed Meta's open-source DINOv2 vision model to analyze cancer organoid images and predict patient drug responses in clinical trials. In collaboration with CentraleSupelec and the Jaulin Lab under the RHU ORGANOMIC initiative, the team found DINOv2 outperformed prior specialized models by 26.8% accuracy. The model enabled quantitative extraction of imaging data from organoid videos, replacing labor-intensive frame-by-frame analysis and significantly accelerating their biomedical platform development.